3-(4-氨基苯基)-N-甲基苯甲酰胺 | 1335041-46-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(4-氨基苯基)-N-甲基苯甲酰胺
• 英文名称: 3-(4-Aminophenyl)-N-methylbenzamide
• CAS: 1335041-46-7
• 化学式: C₁₄H₁₄N₂O
• 分子量: 226.278
• InChiKey: FXYJOGOGMBDLHT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  3-(4-氨基苯基)-N-甲基苯甲酰胺 、 4-氯-3-三氟甲基异氰酸苯酯 以 二氯甲烷 为溶剂， 反应 12.0h， 以80.2%的产率得到1-(4-(3-(Methylcarbamoyl)phenyl)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea
  参考文献：
  名称：

  Design, synthesis and evaluation of novel diaryl urea derivatives as potential antitumor agents

  摘要：

  A novel series of diaryl ureas containing different linker groups were designed and synthesized. Their in vitro antitumor activity against MX-1, A375, HepG2, Ketr3 and HT-29 was evaluated using the standard MIT assay. Compounds having a rigid linker group such as vinyl, ethynyl and phenyl showed significant inhibitory activity against a variety of cancer cell lines. Specifically, compound 23 with a phenyl linker group demonstrated broad-spectrum antitumor activity with IC50 values of 5.17-6.46 mu M against five tested tumor cell lines. Compound 23 is more potent than reference drug sorafenib (8.27-15.2 mu M), representing a promising lead for further optimization. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.03.020
• 作为产物：
  描述：

  4-硝基联苯-3-羧酸 在 氯化亚砜 、 5%-palladium/activated carbon 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 16.0h， 生成 3-(4-氨基苯基)-N-甲基苯甲酰胺
  参考文献：
  名称：

  Design, synthesis and evaluation of novel diaryl urea derivatives as potential antitumor agents

  摘要：

  A novel series of diaryl ureas containing different linker groups were designed and synthesized. Their in vitro antitumor activity against MX-1, A375, HepG2, Ketr3 and HT-29 was evaluated using the standard MIT assay. Compounds having a rigid linker group such as vinyl, ethynyl and phenyl showed significant inhibitory activity against a variety of cancer cell lines. Specifically, compound 23 with a phenyl linker group demonstrated broad-spectrum antitumor activity with IC50 values of 5.17-6.46 mu M against five tested tumor cell lines. Compound 23 is more potent than reference drug sorafenib (8.27-15.2 mu M), representing a promising lead for further optimization. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.03.020